C12Y 204/02036
Nad--diphthamide adp-ribosyltransferase
Official title: NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
C12Y204/02036 (Nad--diphthamide adp-ribosyltransferase) appears on 76 US grants and 134 published applications in this corpus.
Search patents in C12Y- Granted patents
- 76
- Published applications
- 134
- Assignees
- 63
- Inventors
- 225
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 2 |
| 2010 | 0 | 1 |
| 2011 | 0 | 4 |
| 2012 | 1 | 3 |
| 2013 | 3 | 4 |
| 2014 | 2 | 5 |
| 2015 | 3 | 14 |
| 2016 | 10 | 13 |
| 2017 | 7 | 23 |
| 2018 | 10 | 8 |
| 2019 | 7 | 11 |
| 2020 | 13 | 1 |
| 2021 | 3 | 12 |
| 2022 | 6 | 9 |
| 2023 | 1 | 6 |
| 2024 | 3 | 9 |
| 2025 | 5 | 6 |
| 2026 | 2 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Vaccine21 Jul 2026US 12,685,769 B2Glaxosmithkline Biologicals SA
- De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals26 May 2026US 12,637,495 B2Molecular Templates, Inc.
- Molecular signature of cancer23 Sep 2025US 12,419,934 B2Wake Forest University Health Sciences
- Chimeric protein toxins for expression by therapeutic bacteria5 Aug 2025US 12,378,536 B1
- Polypeptide composition20 May 2025US 12,305,202 B2Jecho Institute, Co., Ltd.
- Multivalent vaccine compositions and uses thereof23 Jul 2026US 2026/0207726 A1Glaxosmithkline Biologicals SA
- Bioconjugate compositions and process for bioconjugate production16 Jul 2026US 2026/0199454 A1Janssen Pharmaceuticals, Inc.
- Immunotoxin for cancer immunotherapy21 May 2026US 2026/0137777 A1The Regents of the University of Colorado, a body corporate
- Antl-cmpl divalent scfv and uses thereof28 Aug 2025US 2025/0270334 A1The United States of America, as represented by the Secretary, Department of Health and Human
- Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo14 Aug 2025US 2025/0255938 A1Thornhill Therapeutics, Inc.
Most cited
By later US patents
- Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties22US 10,815,469 B2Molecular Templates, Inc. · 2020
- Modified forms of Pseudomonas exotoxin A21US 9,677,055 B2Interxon Corporation · 2017
- IL3Rα antibody conjugates and uses thereof18US 8,163,279 B2Stemline Therapeutics, Inc. · 2012
- Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences17US 9,090,691 B2Applied Molecular Transport Inc. · 2015
- Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo14US 10,130,688 B2Applied Molecular Transport Inc. · 2018